{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:29:01Z","timestamp":1784298541713,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00894-021-05010-w","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T06:02:42Z","timestamp":1640671362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5250-003X","authenticated-orcid":false,"given":"Hezha O.","family":"Rasul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhtyar K.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dlzar D.","family":"Ghafour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Kivrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"5010_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-38332-6","volume":"9","author":"KB Lokhande","year":"2019","unstructured":"Lokhande KB, Nagar S, Swamy KV (2019) Molecular interaction studies of Deguelin and its derivatives with Cyclin D1 and Cyclin E in cancer cell signaling pathway: the computational approach. Sci Rep 9:1\u201313","journal-title":"Sci Rep"},{"key":"5010_CR2","doi-asserted-by":"publisher","first-page":"103842","DOI":"10.1016\/j.compbiomed.2020.103842","volume":"122","author":"A Rampun","year":"2020","unstructured":"Rampun A, Morrow PJ, Scotney BW, Wang H (2020) Breast density classification in mammograms: an investigation of encoding techniques in binary-based local patterns. Comput Biol Med 122:103842","journal-title":"Comput Biol Med"},{"key":"5010_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40659-017-0140-9","volume":"50","author":"M Akram","year":"2017","unstructured":"Akram M, Iqbal M, Daniyal M, Khan AU (2017) Awareness and current knowledge of breast cancer. Biol Res 50:1\u201323","journal-title":"Biol Res"},{"key":"5010_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3109\/13697137.2013.768806","volume":"16","author":"H Kuhl","year":"2013","unstructured":"Kuhl H, Schneider HPG (2013) Progesterone\u2013promoter or inhibitor of breast cancer. Climacteric 16:54\u201368","journal-title":"Climacteric"},{"key":"5010_CR5","doi-asserted-by":"crossref","unstructured":"Saha Roy S, Vadlamudi RK (2012) Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2012","DOI":"10.1155\/2012\/654698"},{"key":"5010_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrc3093","volume":"11","author":"C Thomas","year":"2011","unstructured":"Thomas C, Gustafsson J-\u00c5 (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597\u2013608","journal-title":"Nat Rev Cancer"},{"key":"5010_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1677\/erc.0.0100193","volume":"10","author":"SI Hayashi","year":"2003","unstructured":"Hayashi SI, Eguchi H, Tanimoto K et al (2003) The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10:193\u2013202","journal-title":"Endocr Relat Cancer"},{"key":"5010_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/ctrv.2001.0235","volume":"27","author":"AK Salih","year":"2001","unstructured":"Salih AK, Fentiman IS (2001) Breast cancer prevention: present and future. Cancer Treat Rev 27:261\u2013273","journal-title":"Cancer Treat Rev"},{"key":"5010_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.mce.2015.04.017","volume":"418","author":"Z-Y Wang","year":"2015","unstructured":"Wang Z-Y, Yin L (2015) Estrogen receptor alpha-36 (ER-\u03b136): a new player in human breast cancer. Mol Cell Endocrinol 418:193\u2013206","journal-title":"Mol Cell Endocrinol"},{"key":"5010_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-52162-0","volume":"9","author":"R Acharya","year":"2019","unstructured":"Acharya R, Chacko S, Bose P et al (2019) Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Sci Rep 9:1\u201313","journal-title":"Sci Rep"},{"key":"5010_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02893416","volume":"12","author":"J Kiani","year":"2006","unstructured":"Kiani J, Khan A, Khawar H et al (2006) Estrogen receptor \u03b1-negative and progesterone receptor-positive breast cancer: Lab error or real entity? Pathol Oncol Res 12:223\u2013227","journal-title":"Pathol Oncol Res"},{"key":"5010_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ctrv.2016.12.010","volume":"53","author":"R Costa","year":"2017","unstructured":"Costa R, Shah AN, Santa-Maria CA et al (2017) Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development. Cancer Treat Rev 53:111\u2013119","journal-title":"Cancer Treat Rev"},{"key":"5010_CR13","doi-asserted-by":"publisher","first-page":"26560","DOI":"10.18632\/oncotarget.5306","volume":"6","author":"G Palma","year":"2015","unstructured":"Palma G, Frasci G, Chirico A et al (2015) Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 6:26560","journal-title":"Oncotarget"},{"key":"5010_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2174\/1573409914666180228111433","volume":"14","author":"PS Reddy","year":"2018","unstructured":"Reddy PS, Lokhande KB, Nagar S et al (2018) Molecular modeling, docking, dynamics and simulation of gefitinib and its derivatives with EGFR in non-small cell lung cancer. Curr Comput Aided Drug Des 14:246\u2013252","journal-title":"Curr Comput Aided Drug Des"},{"key":"5010_CR15","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/ijms21061960","volume":"21","author":"L Ding","year":"2020","unstructured":"Ding L, Cao J, Lin W et al (2020) The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 21:1960","journal-title":"Int J Mol Sci"},{"key":"5010_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr927","volume":"6","author":"H Carraway","year":"2004","unstructured":"Carraway H, Hidalgo M (2004) New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6:1\u20136","journal-title":"Breast Cancer Res"},{"key":"5010_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S","volume":"95","author":"JMW Gee","year":"2001","unstructured":"Gee JMW, Robertson JFR, Ellis IO, Nicholson RI (2001) Phosphorylation of ERK1\/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J cancer 95:247\u2013254","journal-title":"Int J cancer"},{"key":"5010_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1074\/mcp.M111.015750","volume":"11","author":"IM Ferrando","year":"2012","unstructured":"Ferrando IM, Chaerkady R, Zhong J et al (2012) Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 11:355\u2013369","journal-title":"Mol Cell Proteomics"},{"key":"5010_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/ph5091008","volume":"5","author":"F Zagouri","year":"2012","unstructured":"Zagouri F, Bournakis E, Koutsoukos K, Papadimitriou CA (2012) Heat shock protein 90 (hsp90) expression and breast cancer. Pharmaceuticals 5:1008\u20131020","journal-title":"Pharmaceuticals"},{"key":"5010_CR20","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1002\/cam4.3014","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu H, Yang Z, Lu W et al (2020) Chemokines and chemokine receptors: a new strategy for breast cancer therapy. Cancer Med 9:3786\u20133799","journal-title":"Cancer Med"},{"key":"5010_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2015.00012","volume":"6","author":"M Vela","year":"2015","unstructured":"Vela M, Aris M, Llorente M et al (2015) Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol 6:12","journal-title":"Front Immunol"},{"key":"5010_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-600","volume":"13","author":"I Al-Sharif","year":"2013","unstructured":"Al-Sharif I, Remmal A, Aboussekhra A (2013) Eugenol triggers apoptosis in breast cancer cells through E2F1\/survivin down-regulation. BMC Cancer 13:1\u201310","journal-title":"BMC Cancer"},{"key":"5010_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-018-2392-5","volume":"18","author":"ML Abdullah","year":"2018","unstructured":"Abdullah ML, Hafez MM, Al-Hoshani A, Al-Shabanah O (2018) Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells. BMC Complement Altern Med 18:1\u201311","journal-title":"BMC Complement Altern Med"},{"key":"5010_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mc.22758","volume":"57","author":"SS Islam","year":"2018","unstructured":"Islam SS, Al-Sharif I, Sultan A et al (2018) Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-\u03baB signaling pathway. Mol Carcinog 57:333\u2013346","journal-title":"Mol Carcinog"},{"key":"5010_CR25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/nu9121367","volume":"9","author":"DP Bezerra","year":"2017","unstructured":"Bezerra DP, Milit\u00e3o GCG, De Morais MC, De Sousa DP (2017) The dual antioxidant\/prooxidant effect of eugenol and its action in cancer development and treatment. Nutrients 9:1367","journal-title":"Nutrients"},{"key":"5010_CR26","doi-asserted-by":"publisher","first-page":"56296","DOI":"10.18632\/oncotarget.17626","volume":"8","author":"M Ma","year":"2017","unstructured":"Ma M, Ma Y, Zhang G-J et al (2017) Eugenol alleviated breast precancerous lesions through HER2\/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest. Oncotarget 8:56296","journal-title":"Oncotarget"},{"key":"5010_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-13505-x","volume":"7","author":"X Yan","year":"2017","unstructured":"Yan X, Zhang G, Bie F et al (2017) Eugenol inhibits oxidative phosphorylation and fatty acid oxidation via downregulation of c-Myc\/PGC-1\u03b2\/ERR\u03b1 signaling pathway in MCF10A-ras cells. Sci Rep 7:1\u201313","journal-title":"Sci Rep"},{"key":"5010_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/1759-7714.12508","volume":"9","author":"L Fangjun","year":"2018","unstructured":"Fangjun L, Zhijia Y (2018) Tumor suppressive roles of eugenol in human lung cancer cells. Thorac Cancer 9:25\u201329","journal-title":"Thorac Cancer"},{"key":"5010_CR29","first-page":"519","volume":"26","author":"A Hussain","year":"2011","unstructured":"Hussain A, Brahmbhatt K, Priyani A et al (2011) Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells. Cancer Biother Radiopharm 26:519\u2013527","journal-title":"Cancer Biother Radiopharm"},{"key":"5010_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1590\/S0103-50532008000300024","volume":"19","author":"AH Carrasco","year":"2008","unstructured":"Carrasco AH, Espinoza CL, Cardile V et al (2008) Eugenol and its synthetic analogues inhibit cell growth of human cancer cells (Part I). J Braz Chem Soc 19:543\u2013548","journal-title":"J Braz Chem Soc"},{"key":"5010_CR31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1039\/D0FO02105A","volume":"12","author":"P Choudhury","year":"2021","unstructured":"Choudhury P, Barua A, Roy A et al (2021) Eugenol emerges as an elixir by targeting \u03b2-catenin, the central cancer stem cell regulator in lung carcinogenesis: an in vivo and in vitro rationale. Food Funct 12:1063\u20131078","journal-title":"Food Funct"},{"key":"5010_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z et al (2000) The protein data bank. Nucleic Acids Res 28:235\u2013242","journal-title":"Nucleic Acids Res"},{"key":"5010_CR33","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.bmcl.2007.01.054","volume":"17","author":"KD Dykstra","year":"2007","unstructured":"2IOK, Dykstra KD, Guo L, Birzin ET et al (2007) Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ER\u03b1. Bioorg Med Chem Lett 17:2322\u20132328","journal-title":"Bioorg Med Chem Lett"},{"key":"5010_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jsbmb.2014.08.008","volume":"144","author":"I Petit-Topin","year":"2014","unstructured":"4OAR, Petit-Topin I, Fay M, Resche-Rigon M et al (2014) Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors. J Steroid Biochem Mol Biol 144:427\u2013435","journal-title":"J Steroid Biochem Mol Biol"},{"key":"5010_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","volume":"11","author":"C-H Yun","year":"2007","unstructured":"2J6M, Yun C-H, Boggon TJ, Li Y et al (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217\u2013227","journal-title":"Cancer Cell"},{"key":"5010_CR36","doi-asserted-by":"publisher","first-page":"10176","DOI":"10.1021\/jm501578n","volume":"57","author":"EJ Hanan","year":"2014","unstructured":"4RJ3, Hanan EJ, Eigenbrot C, Bryan MC et al (2014) Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. J Med Chem 57:10176\u201310191","journal-title":"J Med Chem"},{"key":"5010_CR37","doi-asserted-by":"crossref","unstructured":"4DRH: M\u00e4rz AM, Fabian A-K, Kozany C et al (2013) Large FK506-binding proteins shape the pharmacology of rapamycin. Mol Cell Biol 33:1357\u20131367","DOI":"10.1128\/MCB.00678-12"},{"key":"5010_CR38","doi-asserted-by":"crossref","unstructured":"2A9I: Lasker M V, Gajjar MM, Nair SK (2005) Cutting edge: molecular structure of the IL-1R-associated kinase-4 death domain and its implications for TLR signaling. J Immunol 175:4175\u20134179","DOI":"10.4049\/jimmunol.175.7.4175"},{"key":"5010_CR39","doi-asserted-by":"crossref","unstructured":"2SRC: Xu W, Doshi A, Lei M et al (1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3:629\u2013638","DOI":"10.1016\/S1097-2765(00)80356-1"},{"key":"5010_CR40","doi-asserted-by":"crossref","unstructured":"2VCJ: Brough PA, Aherne W, Barril X et al (2008) 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51:196\u2013218","DOI":"10.1021\/jm701018h"},{"key":"5010_CR41","doi-asserted-by":"crossref","unstructured":"4JL7: Lu G, Wu Y, Jiang Y et al (2013) Structural insights into neutrophilic migration revealed by the crystal structure of the chemokine receptor CXCR2 in complex with the first PDZ domain of NHERF1. PLoS One 8:e76219","DOI":"10.1371\/journal.pone.0076219"},{"key":"5010_CR42","doi-asserted-by":"crossref","unstructured":"3OE6: Wu B, Chien EYT, Mol CD, et al (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (80- ) 330:1066\u20131071","DOI":"10.1126\/science.1194396"},{"key":"5010_CR43","doi-asserted-by":"crossref","unstructured":"4MBS: Tan Q, Zhu Y, Li J, et al (2013) Structure of the CCR5 chemokine receptor\u2013HIV entry inhibitor maraviroc complex. Science (80- ) 341:1387\u20131390","DOI":"10.1126\/science.1241475"},{"key":"5010_CR44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461","journal-title":"J Comput Chem"},{"key":"5010_CR45","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","volume":"49","author":"S Kim","year":"2021","unstructured":"Kim S, Chen J, Cheng T et al (2021) PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res 49:D1388\u2013D1395","journal-title":"Nucleic Acids Res"},{"key":"5010_CR46","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling T, Irwin JJ (2015) ZINC 15\u2013ligand discovery for everyone. J Chem Inf Model 55:2324\u20132337","journal-title":"J Chem Inf Model"},{"key":"5010_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-2946-3-1","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle NM, Banck M, James CA et al (2011) Open Babel: an open chemical toolbox. J Cheminform 3:1\u201314","journal-title":"J Cheminform"},{"key":"5010_CR48","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074\u2013D1082","journal-title":"Nucleic Acids Res"},{"key":"5010_CR49","unstructured":"Molinspiration Cheminformatics. In: Nov. ulica. https:\/\/www.molinspiration.com\/"},{"key":"5010_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","volume":"44","author":"CA Lipinski","year":"2000","unstructured":"Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235\u2013249","journal-title":"J Pharmacol Toxicol Methods"},{"key":"5010_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijpharm.2018.07.046","volume":"549","author":"CM Chagas","year":"2018","unstructured":"Chagas CM, Moss S, Alisaraie L (2018) Drug metabolites and their effects on the development of adverse reactions: revisiting Lipinski\u2019s Rule of Five. Int J Pharm 549:133\u2013149","journal-title":"Int J Pharm"},{"key":"5010_CR52","unstructured":"Release S (2017) 3: Desmond molecular dynamics system, DE Shaw research, New York, NY, 2017. Maest Interoperability Tools, Schr\u00f6dinger, New York, NY"},{"key":"5010_CR53","doi-asserted-by":"publisher","first-page":"480","DOI":"10.5530\/jyp.2017.9.94","volume":"9","author":"R Pushpalatha","year":"2017","unstructured":"Pushpalatha R, Selvamuthukumar S, Kilimozhi D (2017) Comparative insilico docking analysis of curcumin and resveratrol on breast cancer proteins and their synergistic effect on MCF-7 cell line. J Young Pharm 9:480","journal-title":"J Young Pharm"},{"key":"5010_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-38671-y","volume":"9","author":"A DeBono","year":"2019","unstructured":"DeBono A, Thomas DR, Lundberg L et al (2019) Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity. Sci Rep 9:1\u201319","journal-title":"Sci Rep"},{"key":"5010_CR55","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/bjc.2017.298","volume":"117","author":"M Barzegar","year":"2017","unstructured":"Barzegar M, Ma S, Zhang C et al (2017) SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling. Br J Cancer 117:1154\u20131163","journal-title":"Br J Cancer"},{"key":"5010_CR56","first-page":"845","volume":"9","author":"Z Liu","year":"2017","unstructured":"Liu Z, Wang F, Zhou Z-W et al (2017) Alisertib induces G2\/M arrest, apoptosis, and autophagy via PI3K\/Akt\/mTOR-and p38 MAPK-mediated pathways in human glioblastoma cells. Am J Transl Res 9:845","journal-title":"Am J Transl Res"},{"key":"5010_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.compbiolchem.2016.08.007","volume":"64","author":"Y Ding","year":"2016","unstructured":"Ding Y, Fang Y, Moreno J et al (2016) Assessing the similarity of ligand binding conformations with the Contact Mode Score. Comput Biol Chem 64:403\u2013413","journal-title":"Comput Biol Chem"},{"key":"5010_CR58","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/molecules21111575","volume":"21","author":"MJ Garc\u00eda-Godoy","year":"2016","unstructured":"Garc\u00eda-Godoy MJ, L\u00f3pez-Camacho E, Garc\u00eda-Nieto J et al (2016) Molecular docking optimization in the context of multi-drug resistant and sensitive EGFR mutants. Molecules 21:1575","journal-title":"Molecules"}],"updated-by":[{"DOI":"10.1007\/s00894-022-05068-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000}}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-021-05010-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-021-05010-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-021-05010-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T22:23:05Z","timestamp":1700000585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-021-05010-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5010"],"URL":"https:\/\/doi.org\/10.1007\/s00894-021-05010-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00894-022-05068-0","asserted-by":"object"}]},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00894-022-05068-0","URL":"https:\/\/doi.org\/10.1007\/s00894-022-05068-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studied with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17"}}